Goldman Sachs, Leerink and Evercore ISI acted as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences: Hold Rating Amid Uncertain Future for Casdatifan and Competitive Challenges
- Arcus Biosciences presents new data for casdatifan
- Arcus says new data demonstrated ‘best-in-class potential’ for casdatifan
- Arcus Biosciences to present new data from Casdatifan at 2025 ASCO
- Arcus Biosciences Appoints New Board Director